SEPETAPROST

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H36F2O6
Molecular Weight	482.5572
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)OC(=O)CCC[C@H]1CC[C@H]2[C@H](C[C@@H](O)[C@@H]2\C=C\[C@@H](O)COC3=CC(F)=CC=C3F)OC1

InChI

InChIKey=BKVUSNOUTQMSBE-XCMGCKIWSA-N

InChI=1S/C26H36F2O6/c1-16(2)34-26(31)5-3-4-17-6-9-21-20(23(30)13-24(21)32-14-17)10-8-19(29)15-33-25-12-18(27)7-11-22(25)28/h7-8,10-12,16-17,19-21,23-24,29-30H,3-6,9,13-15H2,1-2H3/b10-8+/t17-,19+,20+,21+,23+,24-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C26H36F2O6
Molecular Weight	482.5572
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26720443 | https://clinicaltrials.gov/ct2/show/NCT02083289

Sepetoprost (also known as ONO-9054), prostaglandin analog was developed as a dual agonist of prostaglandin E3 (EP3) and prostaglandin F (FP) receptors. It is known, that the use of a dual prostaglandin EP3 and prostaglandin F receptor agonists is a novel approach for the reduction of intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Sepetoprost was successfully studied in clinical trials phase II for the treatment of open-angle glaucoma, ocular hypertension, and mild open angle-glaucoma.

Originator

Approval Year

PubMed

Title	Date	PubMed
Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma.	2019-04	29669171
Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study.	2016-10	27300645
A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers.	2015-12	26720443

Patents

Sample Use Guides

In Vivo Use Guide

Nine subjects were randomized to each of ONO-9054 (sepetaprost) 3, 10, 20, 30 μg/mL and 12 to placebo. Subjects received a single drop to each eye at 07:00±30 minutes (single dose). Following a 4-day no-treatment period, subjects were dosed once daily for 14 consecutive days (multiple day dosing)

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:50:34 GMT 2025` Edited by `admin` on `Mon Mar 31 22:50:34 GMT 2025`
Record UNII	79O7855J4G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ONO-9054

Preferred Name

English

SEPETAPROST

Official Name

English

DE-126

Code

English

2H-CYCLOPENT(B)OXEPIN-3-BUTANOIC ACID, 6-((1E,3R)-4-(2,5-DIFLUOROPHENOXY)-3-HYDROXY-1-BUTEN-1-YL)OCTAHYDRO-7-HYDROXY-, 1-METHYLETHYL ESTER, (3S,5AR,6R,7R,8AS)-

Systematic Name

English

2-PROPANYL 4-((3S,5AR,6R,7R,8AS)-6-((1E,3R)-4-(2,5-DIFLUOROPHENOXY)-3-HYDROXY-1-BUTEN-1-7-HYDROXYOCTAHYDRO-2H-CYCLOPENTA(B)OXEPIN-3-YL)BUTANOATE

Systematic Name

English

STN-1012600

Code

English

Sepetaprost [WHO-DD]

Common Name

English

STN1012600

Code

English

sepetaprost [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29705